



Optiscan Imaging Ltd

FY21 Annual Results Presentation

Notice

This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 30 August 2021.

The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may require in evaluating a possible investment in OIL or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Neither OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to update any information subsequent to the issue of this presentation.

Future Performance

This presentation contains certain forward-looking statements and unaudited information including regarding the Company's future growth plans, strategies, products, operating performance, milestones, guidance, opinions, estimates, targets, goals, forecasts, earnings and financial position (Forward Looking Statements). The Forward Looking Statements, in this presentation are based on assumptions and contingencies which are subject to change without notice. Actual results and achievements could be significantly different from those expressed in or implied by this presentation. The Forward Looking Statements involve subjective judgements and assumptions as to future events which may or may not be correct and should not be relied upon as an indication or guarantee of future performance. No representation, warranty or assurance (express or implied) is given or made in relation to the achievement of any Forward Looking Statement by any person (including OIL).

Subject to any continuing obligations under applicable law, OIL disclaims any obligation or undertaking to provide any updates or revisions to any Forward Looking Statement in this presentation to reflect any change in expectations in relation to any such Forward Looking Statement or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will create an implication that there has been no change in the affairs of OIL since the date of this presentation.

Past performance

The operating and historical financial information in this presentation not an indication of OIL's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. Past performance of OIL is not and cannot be relied upon as an indicator of (and provides no guidance as to) future performance.

Notice

Not an offer or financial product advice

This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure document required under the Corporations Act. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire securities and does not and will not form any part of any contract for acquisition of securities. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation (including, without limitation, the assumptions, uncertainties and contingencies which may affect the future operations of OIL and the impact that different future outcomes may have on OIL).

This presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in OIL's shares is subject to known and unknown risks, some of which are beyond the control of OIL. OIL does not guarantee any particular rate of return or the performance of OIL.

Liability

Neither OIL nor any of its officers, employees, officers, agents, consultants or advisers owe any duty (whether in equity, in tort or otherwise) to any investor in connection with this presentation nor do they have any liability (including, without limitation, in negligence) for any loss or damage arising from or in connection with this presentation, except to the extent that such liability may not lawfully be excluded.

To the maximum extent permitted by law, you acknowledge and agree that by taking part in this presentation you will not bring or institute any legal proceedings in contract, in tort, for breach of statutory duty or otherwise against OIL or any of its officers, employees, officers, agents, consultants or advisers in respect of any information provided to it in or in connection with this presentation.

Optiscan Imaging Transformation in FY21

Major advances towards becoming a global medical imaging and diagnostics company

Optiscan at a glance


Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development of endomicroscopic technology which enables real-time, 'in vivo' imaging of human tissue for cancer screening, diagnoses and in surgery




Develops and manufactures hand-held confocal endomicroscopes for medical and research use



Key clinical device (InVivage®) well progressed down FDA approval pathway for use in oral cancer



Significant doctor and patient benefits through more targeted biopsies and reduced surgical margins



World-leading and patented protected technology



Trials underway for application to other cancers (including breast, cervical, oesophageal)



Co-operation with Carl Zeiss for use of CONVIVO device in neurosurgery



Global market entry and distribution strategy for InVivage® under development
Established distribution network for pre-clinical device FIVE2 across Asia, North America and Australia




Well funded balance sheet to underpin clinical trials and future growth

Optiscan Key Achievements in FY21

- ✓ **Pathway to US FDA approval for use of InVivage® device in Oral Cancer on track**
 - Oral Cancer Clinical Trial to Support FDA approval process underway
 - Internal and third party device testing progressing
 - US market entry planning
- ✓ **Receipt of Federal Government Support**
 - Almost \$1m of funding for Oral Cancer Screening trial in partnership with Melbourne Dental School
- ✓ **Development of Breast Cancer Surgical Margin Assessment clinical application**
 - Commencement and extension of 3 hospital Melbourne trial
- ✓ **Well-funded – Capital Raising of A\$9.8m in September 2020**
- ✓ **Board Invigoration – Mr Robert Cooke appointed Chair and new non-executive directors (Mr Ron Song, Professor Camile Farah and Ms Karen Borg)**

Milestones and Recent Share Price Movement



FY21 Financial Highlights

FY21 Total Income (operating revenue and other income) of \$2.54m, up ~28% on FY20

- Benefits of new distribution arrangements for FIVE2 - 2 sales in FY21 and order received in July '21;
- Continued orders from CZM with sales of \$500k as part of CONVIVO® co-operation agreement in neurosurgery
- Income from delivery of InVivage® prototype and product development under BioMedtech Horizons grant

FY21 EBITDA of (\$1.85m); FY21 Net operating cash outflow of (\$2.13m)

- Cost increase represents expenditure to underpin future growth including increasing scalability in production and quality assurance; spending on clinical trials, testing requirements, prototypes and FDA consultants
- Maintenance of expense discipline around operating costs

Strengthened balance sheet through a capital raising of \$9.8m

FY21 Profit and Loss, Balance Sheet and Cash Flow

Profit and Loss*

	FY20	FY21	
Revenue	\$940k	\$500k	<i>Carl Zeiss Co-operation</i>
	\$170k	\$370k	<i>FIVE2 Sales</i>
	\$80k	\$20k	<i>FIVE2 Rental and other</i>
	\$1,190k	\$890k	Total
Other Income		\$510k	<i>Melbourne Dental School Grant</i>
	\$790k	\$1,120k	<i>R&D Tax Incentive, Other Govt Support</i>
		\$20k	<i>Interest</i>
Total Income	\$1,980k	\$2,540k	
Operating Expenses	(\$3,150k)	(\$4,200k)	<i>5 new staff to support business growth; FDA Consultant and testing costs</i>
EBITDA	(\$1,470k)	(\$1,850k)	
NPAT	(\$1,770k)	(\$2,130k)	

Cash Flow*

	FY20	FY21	
Cashflow from operations	(\$1,400k)	(\$2,130k)	
Cashflow from investing	(\$20k)	(\$30k)	
Cashflow from financing	\$190k	\$10,070k	<i>Capital Raising and exercise of options</i>
Total Cashflows	(\$1,230k)	\$7,920k	

Balance Sheet*

	FY20	FY21	
Current Assets	\$2,510k	\$10,970k	<i>Capital Raising and exercise of options</i>
Non-current Assets	\$940k	\$730k	
Total Assets	\$3,440k	11,700k	
Current Liabilities	(1,240k)	(\$970k)	<i>Repayment of all borrowings</i>
Non-current Liabilities	(\$650k)	(\$510k)	
Total Liabilities	(\$1,900k)	(1,480k)	
Net Assets	\$1,550k	\$10,220k	
Total Equity	\$1,550k	\$10,220k	

* Financials are subject to rounding

Optiscan devices and current positioning

Overview of Optiscan devices

There are currently three devices at different stages of development and marketing, which all use Optiscan's unique hand-held, confocal endomicroscopic technology to deliver real time imaging at sub-cellular level

	InVivage®	FIVE2 (ViewnVivo)	CONVIVO® (co-operation agreement with Carl Zeiss Meditec)
Stage	Seeking FDA approval for Oral Cancer	Production and distribution	Production and distribution
Overview	Clinical device	Pre-clinical device used in laboratory and translational experiments	Co-operation agreement with Carl Zeiss Meditec
Applications and Users	- Oral cancer screening and surgery - Breast cancer surgery - Cervical cancer screening and surgery Hospitals and Cancer Centres	- Pre-clinical and translational research - Ex vivo human studies Medical research facilities and universities	Neurosurgery / brain cancer Hospitals and Cancer Centres
Status	- Preparing 510(k) application for clearance in US (FDA) - Multiple clinical trials and studies in Australia and US	- Sales of A\$370k in FY21 - Distributor network: China, Taiwan, South Korea, North America and Aust - First Australian order received in July 2021	- Sales of A\$500k in FY21 - Approved for use in US (FDA) Europe (CE Mark) and Australia (TGA)

Optiscan InVivage® Clinical Device

- Cancer screening and surgical applications
- Miniaturised hand-held probe (4mm diameter tip)
- Instantaneous, sub-cellular resolution imaging
- Enabling more targeted biopsies and reduced surgical margins
- Digital transmission of images
- Initially targeting Oral Cancer Screening and Surgery
- Melbourne Dental Hospital trial of up to 150 patients, 91 sets of imaging completed.

Clinical Applications:

Oral Cancer



Breast Cancer



Cervical Cancer



“Within the next 10 years, the use of digital microscopy will be quite commonplace across many medical specialties”


Dr Tami Yap, Chief Investigator, Melbourne Dental School



Advantages of InVivage® over Current Standard of Care

Screening applications (Oral and Cervical)

- Instantaneous, high-resolution images to enable fewer and more targeted biopsies
- Non-invasive image capture encourages screening and early detection
- Changes in cellular architecture not visible to the naked eye can be monitored over time



Surgical applications (Oral and Cervical)

- Tumour margin can be imaged and assessed at microscopic level
- Instantaneous image capture versus 2 or 3 days for pathology results
- Reduced healthy tissue surrounding tumours in sensitive areas (mouth) need to be removed
- Tumourous cells are removed to reduce repeat operations
- 4mm diameter probe tip lends itself to use in multiple parts of body



InVivage® FDA approval process update

Optiscan is preparing a submission for 510(k) clearance for FDA approval for InVivage® device's use in oral cancer screening and surgery in the United States. Optiscan has successfully passed multiple external and internal tests on its pathway to lodging its submission and is currently completing the remaining tests and activities.

FDA approval process

- 510(k) submission - FDA reduced timeframe pathway
- Demonstrate device is as safe and effective (substantially equivalent) as a similar legally marketed device
- Submission to take place once all validation, verification and clinical trial activities are successfully completed
- Following submission, average time to clearance is approximately six months

Current status

- Q-Submission process undertaken – Optiscan received targeted FDA feedback
- Verification and validation activities are being undertaken internally and with overseas independent contract testing laboratories. Dosing study completed and clinical study underway at Melbourne Dental School.

Optiscan's FIVE2 (ViewnVivo) pre-clinical device

- Designed for translational and pre-clinical research
- Research findings from FIVE2 (ViewnVivo) in the laboratory are transferrable to InVivage®'s use in human patients
- New distribution arrangements commenced in North America, Taiwan and South Korea
- Completed 2 sales in China and received 1st Australian sales order
- Continuing to work closely with overseas distributors and will resume live demonstrations when COVID restrictions permit (a key component of the sales process)

“Optiscan’s FIVE2 confocal laser endomicroscope delivers a crisp image of ligament and tendon fibre structure simultaneous with fluorescence imaging in a robust and easy to use package. Do you want the ability to collect “big microscope” data where only a millimetre-scale object can fit? Optiscan’s CLE is a powerful tool for tissues research and medical diagnosis”

Prof. Mark M. Banaszak Holl, Professor and Head, Department of Chemical Engineering, Monash University



ZEISS CONVIVO® – Carl Zeiss Meditec AG (CZM) Co-operation

- The ZEISS CONVIVO® demonstrates how Optiscan's confocal imaging technology can be customised for specific medical applications
- Through close collaboration with CZM, Optiscan's technology is now being used in neurosurgery
- In recent years CONVIVO® has received FDA 510(k) clearance, CE Mark and TGA approval
- Current trials underway and approved in Europe, the United States and Australia are expected to increase endorsement and publicity from leading neurosurgeons
- While some marketing activities have been impacted by COVID-19 restrictions, Carl Zeiss have continued to make sales of the CONVIVO in Europe and North America during the pandemic



***“This probably is the most exciting technology that I have seen in my career come through the laboratory.” - Dr. Mark C. Preul (MD),
Neurosurgeon, Barrow Neurosurgical Institute, Arizona, United States.***

Optiscan – Clinical Studies




Oral Cancer

- 150 patient Oral Cancer Study at Melbourne Dental School (ranked #14 in world) funded by Australian Government BioMedtech Horizons Program. 91 sets of imaging completed
- Oral Cancer Study at Memorial Sloan Kettering Cancer Centre in New York (#2 cancer centre in US)
- Oral Cancer Screening Study at Australian Centre for Oral Oncology Research and Education in Perth
- 30 patient ex vivo study to commence at Adelaide Dental School (ranked #25 in world)



Breast Cancer

- Ex vivo lumpectomy and mastectomy study at Western Australia's largest private hospital.
- Breast Cancer Intraoperative Assessment Trial (ex vivo study) at Royal Melbourne, Frances Perry, Epworth Hospitals: Imaging of 33 of 40 patients completed to date.



Cervical & Oesophageal Cancer

- Ex vivo studies at Memorial Sloan Kettering Cancer Centre with planning for in vivo studies to commence

Optiscan's relationships and partnerships

Optiscan's established relationships with leading global medical technology companies, universities and hospitals are a strong endorsement of its unique technology. Examples include:



Working with two highest ranked dental schools in Australia

- University of Melbourne (ranked #14 in world)
- University of Adelaide (ranked #25 in world)



Memorial Sloan Kettering
Cancer Center™

Memorial Sloan Kettering,
New York (2nd ranked US
cancer centre)

- Oral cancer (re-agent trial)
- Cervical and oesophageal cancer studies



Carl Zeiss
Meditec AG

Co-operation agreement for
CONVIVO®



Breast cancer trial at leading
Melbourne hospitals

- Royal Melbourne Hospital
- Frances Perry
- Epworth Hospital



Epworth

Frances Perry House
Part of Ramsay Health Care

BARROW
Neurological Institute

Barrow Neurosurgical
Institute, Arizona

- One of most highly regarded neurological centres in US
- Neurosurgery clinical studies



Tissue culture
collaboration



MONASH
University

ACL injury
study

Improving survival rates for oral cancer through early diagnosis

World Lip & Oral Cavity Cancer Incidence And Mortality

Early diagnosis is critical due to the rapidly declining survival rates as cancer progresses
Historically patients have delayed screening of oral lesions due to invasive nature of traditional biopsies and benign nature of many lesions
Optiscan's InVivage can provide a new standard of care to assist increased early diagnosis

2%

Of all cancer
incidence¹

178k

Total deaths 2020¹

378k

New cases 2020¹

Late
diagnosis
survival rate²
57%

InVivage: Non-
invasive, rapid
screening to
diagnose oral
cancer early

Early
diagnosis
survival rate²
>80%

1. Global cancer statistics 2020: GLOBOCAN estimates

2. Pollaers, K., et al., The economic burden of oral squamous cell carcinoma in Australia. Journal of Oral Pathology & Medicine, 2019. 48(7): p. 588-594. doi: 10.1111/jop.12907. Epub 2019 Jun 27.

Improving patient and hospital outcomes in breast cancer

Breast cancer is most common cancer in women

**2.3
Million**

2.3 million new worldwide cases
of breast cancer in 2020¹

15%

15% of all new cancer cases in the
US are breast cancer²

11.1%

11.1% of all new cancer cases
in China are breast cancer¹

- **20-30% of lumpectomy patients currently require repeat surgery** with current practice (histopathology analysis) often taking 2 to 3 days post initial surgery
- Using InVivage® for detection and treatment of positive tumour margin at the time of surgery will **reduce the requirement for repeat surgeries** with reduced emotional trauma, physical pain and costs for patient and hospital

1. Global cancer statistics 2020: GLOBOCAN estimates
2. American Cancer Society Estimated 2020 statistics

FY22 priorities and conclusions

FY22 Key Priorities

- Lodgment of FDA 510(k) oral cancer screening and surgical submission
- Finalise distribution strategy for InVivage® into United States market
- Plan regulatory submissions for InVivage® into European and other markets
- Undertake additional clinical studies in oral and other cancer applications
- Enhanced marketing of FIVE2 device in Australia and overseas
- Continue and enhance co-operation with Carl Zeiss Meditec
- Machine-based learning interpretation of images functionality

Conclusions

- Optiscan's technology changing standard of care for human cancer screening and surgery
- Portfolio of world leading patent protected imaging technology
- Well-progressed on FDA approval process for the use of the InVivage® device in oral cancer in US
- Significant interest and endorsement from medical community in InVivage®, with enhanced patient outcomes:
 - Early and less invasive detection
 - Reduced and more targeted biopsies
 - Reduction of tumor margin in surgery
 - Quicker turnaround times for results
- Growing pipeline of sales for FIVE2 pre-clinical device following a strengthening of the distribution network
- Ongoing sales from co-operation agreement with Carl Zeiss Meditec

Optiscan is on the verge of the next stage in its exciting journey, as it seeks FDA approval for its InVivage® device for use in oral cancer, and trials are continuing in relation to other cancers and applications